Aug. 18 at 10:14 PM
$SURG Would appreciate if someone can clear this up please. Is this accurate?
SurgePays received Nasdaq deficiency notices in March 2026 for failing both the
$35 million market value of listed securities (MVLS) test and the
$1.00 minimum bid price requirement.
180-day cure deadlines: September 14, 2026 for the MVLS deficiency and September 21, 2026 for the minimum bid price deficiency.????
To cure MVLS, market value of listed securities must close at or above
$35,000,000 for at least ten consecutive business days; to cure bid price, the stock must close at or above
$1.00 for at least ten consecutive business days during the compliance window. ????
These notices don’t halt trading immediately, but failure to cure by the deadlines starts the formal delisting process (with a possible hearing/appeal).
So what is the CEO’s strategy to remedy the situation?